Masimo, global leader in non-invasive technology, has now inked an memorandum of understanding (MOU) with Cloudnine Hospitals to embark on universal congenital heart disease screening initiative. All infants will be screened with Masimo SET technology which is being installed at Cloudnine group facilities: 5 Hospitals & 4 centres in Bengaluru, one hospital in Mumbai, two in Pune, one each at Chennai and Gurgaon.
Congenital heart disease (CHD) is the most common birth defect and is reported in nearly one out of every 100 babies is born. Around 78,000 infants succumb to CHD in India annually. Pulse oximetry screening (POS) is a non-invasive and inexpensive tool allowing early diagnosis of critical congenital heart disease (CCHD).
Cloudnine group, a dedicated maternal, gynecological, neonatal and paediatric care centre in partnership Matrix Partners and Sequoia Capital claims that it has so far maintained zero maternal mortality and 99.83 per cent survival for babies.
“Early detection is key in this fragile patient population,” said Joe Kiani, founder and CEO of Masimo.
“It’s exciting to see the adoption of CCHD screening in India. The adoption of Masimo’s superior SET technology will enhance our existing protocols to provide superior screening for CHD. Universal CCHD screening must be made mandatory for every child born in India,” said Dr. Kishore Kumar, chairman and senior neonatologist, Cloudnine Hospital.
When we developed SET, we did not realize how many new applications our ‘Measure-Through Motion and Low Perfusion’ technology would make possible. So it is especially gratifying that we can help clinicians around the world save the lives of so many babies, said the Masimo chief.